Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer
Authors:
- Massimo CristofanilliMCMassimo Cristofanilli
- Vicente ValeroVVVicente Valero
- Aroop MangalikAMAroop Mangalik
- Melanie RoyceMRMelanie Royce
- Ian RabinowitzIRIan Rabinowitz
- Francis P. ArenaFAFrancis P. Arena
- Joan F. KroenerJKJoan F. Kroener
- Elizabeth CurcioECElizabeth Curcio
- Claire WatkinsCWClaire Watkins
- Sarah BacusSBSarah Bacus
- Elsa M. CoraECElsa M. Cora
- Elizabeth AndersonEAElizabeth Anderson
- 14 March 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (6) , 1904-1914
Abstract
Purpose: This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor–positive metastatic breast cancer (MBC). Experimental Design: Postmenopausal women with hormone receptor–positive measurable or evaluable MBC who had not received prior endocrine therapy for this disease stage or who developed metastatic disease during/after adjuvant tamoxifen were eligible. The primary response variable was progression-free survival (PFS) and secondary response variables included clinical benefit rate, objective response rate, overall survival, safety and tolerability, and pharmacokinetics. Tumor biomarker evaluation was an exploratory objective. Results: Forty-three patients were randomized to anastrozole plus gefitinib and 50 patients were randomized to anastrozole plus placebo of a planned total of 174 patients (enrollment was prematurely discontinued due to slow recruitment). PFS for patients receiving the combination of anastrozole and gefitinib was longer than for patients receiving anastrozole plus placebo [hazard ratio (gefitinib/placebo), 0.55; 95% confidence interval, 0.32-0.94; median PFS, 14.7 versus 8.4 months]. The clinical benefit rate was 49% versus 34%, and the objective response rate was 2% versus 12% with anastrozole plus gefitinib and anastrozole plus placebo, respectively. No evidence of interaction between baseline biomarker levels and relative treatment effect was found. No unexpected adverse events were observed. Conclusion: This small randomized study showed that anastrozole in combination with gefitinib is associated with a marked advantage in PFS compared with anastrozole plus placebo, and that the combination was tolerated in postmenopausal women with hormone receptor–positive MBC. Further investigation of epidermal growth factor receptor inhibition in combination with endocrine therapy may be warranted. Clin Cancer Res; 16(6); 1904–14Keywords
All Related Versions
This publication has 17 references indexed in Scilit:
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyJournal of Clinical Oncology, 2009
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast CancerJournal of Clinical Oncology, 2007
- Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast CancerJournal of Clinical Oncology, 2005
- Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trialThe Lancet Oncology, 2005
- Serum Soluble Epidermal Growth Factor Receptor Concentrations Decrease in Postmenopausal Metastatic Breast Cancer Patients Treated with LetrozoleCancer Research, 2005
- Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast CancersJournal of Clinical Oncology, 2005
- 437 A multicenter phase II trial to evaluate gefitinib (‘Iressa’, ZD1839) (500 mg/day) in patients with metastatic breast cancer after previous chemotherapy treatmentEuropean Journal of Cancer Supplements, 2003